• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Alpha Cognition Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    2/27/25 5:02:53 PM ET
    $ACOG
    Get the next $ACOG alert in real time by email
    false 0001655923 A1 00-0000000 0001655923 2025-02-18 2025-02-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C.  20549

     

    FORM 8-K

     

    Current Report

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported):  February 18, 2025

     

    Alpha Cognition Inc.

    (Exact name of registrant as specified in its charter)

     

    British Columbia   001-42403   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification Number)

     

    1200 - 750 West Pender Street

    Vancouver, British Columbia

      V6C 2T8
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code:  604-564-9244

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
       

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading Symbol   Name of each exchange on which registered:
    Common Shares, no par value   ACOG   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Executive Compensation

     

    On February 18, 2025, upon the recommendation of the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Alpha Cognition Inc. (the “Company”), the Board approved the following compensation packages consisting of a combination of cash and stock options and annual incentive awards for Michael McFadden, the Company’s Chief Executive Officer (the “CEO”) and Lauren D’Angelo, the Company’s Chief Operating Officer (the “COO”), as set forth below:

     

     

    Name  Position  2025 Base Salary   2025 Bonus Target   Stock Option Compensation(1)   Total 
    Michael McFadden  CEO  $625,000   $375,000   $2,500,000   $3,500,000 
    Lauren D’Angelo  COO  $500,000   $300,000   $1,500,000   $2,300,000 

     

    (1)Incentive Stock Options, provided however, that to the extent that the aggregate fair market value of the stock options held by Michael McFadden and Lauren D’Angelo are exercisable for the first time during any calendar year exceeds $100,000, the remainder options will be treated as non-qualified stock options.

     

    The Compensation Committee reached its recommendation regarding the amendments to the executive compensation and incentive awards for the above-named executive officers in consultation with an independent compensation consultant, Global Governance Advisors (“GGA”), which conducted a review of the competitiveness of executive and director compensation levels. As part of GGA’s compensation review process, GGA conducted a comprehensive review that included the review and development of a peer group of 14 companies, for benchmarking executive compensation levels (“Peer Group”), evaluation of total direct compensation (Base Salary plus Short-Term Incentive and Long-Term Incentive) levels and high-level analysis of the Company’s short and long-term incentive design practices (including executive share ownership guidelines) relative to the Peer Group.

     

    The review established that the CEO and COO’s base salaries were positioned below the 25th percentile when compared to the Peer Group. Long term incentives granted to the executives for fiscal 2023 were positioned below the 25th percentile of the market data.

     

    The review recommended and the Compensation Committee determined that the Company’s CEO and COO should be compensated in the 50th percentile in accordance with the Peer Group, with the ability to achieve higher compensation in the case of superior performance. The total compensation consisting of a combination of cash and options were awarded at the discretion of the Compensation Committee and were based on the above-mentioned executive officers’ annual cash bonus and equity targets, as established by the Compensation Committee, and the Compensation Committee’s evaluation of the performance of the above-mentioned executive officers, and approved by the Board.

     

    GGA has used the following criteria to guide the primary Peer Group analysis:

     

    ●Companies of a similar size to the Company (0.25x to 4.5x), primarily from a market cap perspective, but also considering other factors such as cash & cash equivalents;
    ●Companies that are primarily in the pre-commercialization stage;
    ●Companies with a similar business strategy and scope of operations to the Company; and
    ●Publicly traded companies on major North American exchanges (mainly NASDAQ).

      

    1

     

     

    Director Compensation

     

    On February 18, 2025, upon the recommendation of the Compensation Committee, the Board approved the following compensation packages consisting of a combination of cash and stock options for the Board Chair, Board Committee Chairs and Board Members as set forth below:

     

    Name  Position  2025
    Base
    Salary
       Stock
    Option Compensation
       One
    Time
    Stock
    Option
    Grant(1)
       Committee
    Leadership
       Committee
    Assign
       Total 
    Len Mertz  Chair of the Board and Chair of the Audit Committee  $70,000(2)  $95,000   $100,000   $15,000              $280,000 
    Phillip Mertz  Director and Chair of the Compensation Committee  $40,000   $95,000   $100,000   $12,000        $247,000 
    Ken Cawkell  Director, Member of the Compensation Committee and Member of the Governance Committee  $40,000   $95,000   $100,000        $11,000   $246,000 
    John Havens  Director, Chair of the Governance Committee and Member of the Audit Committee  $40,000   $95,000   $100,000   $10,000   $7,500   $252,500 
    Rob Bakshi  Director, Member of the Compensation Committee and Member of the Audit Committee  $40,000   $95,000   $100,000        $13,500   $248,500 
    Rob Wills  Director and member of the Governance Committee  $40,000   $95,000   $100,000        $5,000   $240,00 

     

    (1)As a result of foregone compensation, the Company provided to long-standing non-employee directors a “catch-up” bonus in the form of a special one-time equity award consisting of stock options in the amount of $100,000.
    (2)The Company will pay Len Mertz his salary in the form of stock options in lieu of cash compensation.

     

    The Compensation Committee reached its recommendation regarding the compensation and incentive awards for the above-mentioned Board Chair, Board Committee Chairs and Board Members in consultation with GGA. The Peer Group was used for benchmarking director compensation levels and the Compensation Committee determined that the Company’s Directors should be compensated in the 50th percentile. The Company considered the workload of the Board Chair, Board Committee Chairs and Board Members when adopting the proposed recommendations and that the total compensation would be paid in a combination of cash and options. The Compensation Committee established the annual Board compensation package as a base salary of $40,000 per director ($70,000 for the Chairman), $95,000 in stock option grants, an additional $15,000 for the chair of the Audit Committee, $12,000 for the chair of the Compensation Committee and $10,000 for the chair of the Governance Committee, $7,500 for a member of the Audit Committee, $6,000 to a member of the Compensation Committee and $5,000 to a member of the Governance Committee.

     

    Item 9.01. Financial Statements and Exhibits

     

    (d) Exhibits.

     

    Exhibit Number   Description
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ALPHA COGNITION INC.
       
      By: /s/ Michael McFadden
        Michael McFadden
        Chief Executive Officer
    Dated: February 27, 2025  

     

     

     3

     

     

    Get the next $ACOG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACOG

    DatePrice TargetRatingAnalyst
    3/18/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACOG
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Alpha Cognition Inc.

      DEF 14A - Alpha Cognition Inc. (0001655923) (Filer)

      4/30/25 4:30:51 PM ET
      $ACOG
    • Alpha Cognition Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Alpha Cognition Inc. (0001655923) (Filer)

      4/10/25 4:40:34 PM ET
      $ACOG
    • SEC Form 10-K filed by Alpha Cognition Inc.

      10-K - Alpha Cognition Inc. (0001655923) (Filer)

      3/31/25 4:01:52 PM ET
      $ACOG

    $ACOG
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition's commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer's disease. Ms. Pesa brings 25 years of pharmaceutic

      1/14/25 8:30:00 AM ET
      $ACOG

    $ACOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Alpha Cognition with a new price target

      H.C. Wainwright initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $20.00

      3/18/25 7:48:36 AM ET
      $ACOG

    $ACOG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

      Conference Call Scheduled for May 15, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the schedul

      5/1/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

      Alpha Cognition Inc. (NASDAQ:ACOG) (the "Company" or "Alpha Cognition") today announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (the "AAIC"), taking place July 27–31, 2025 in Toronto, Canada. The presentations will highlight clinical studies supporting ZUNVEYL (benzgalantamine), the Company's lead product and a novel galantamine prodrug approved by the FDA in July 2024 and commercially launched in March 2025. The studies demonstrated bioequivalence to galantamine IR and ER and were integral to the NDA submission and approval. "We're excited to share data that underscore ZUNVEYL's potential to deliver meaningful clinical benefit to patients

      4/28/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Havens John Prentiss

      4 - Alpha Cognition Inc. (0001655923) (Issuer)

      4/29/25 4:41:09 PM ET
      $ACOG
    • SEC Form 4 filed by Director Wills Robert James

      4 - Alpha Cognition Inc. (0001655923) (Issuer)

      4/9/25 9:44:29 PM ET
      $ACOG
    • SEC Form 3 filed by new insider Wills Robert James

      3 - Alpha Cognition Inc. (0001655923) (Issuer)

      4/9/25 9:24:20 PM ET
      $ACOG

    $ACOG
    Financials

    Live finance-specific insights

    See more
    • Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

      Conference Call Scheduled for May 15, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the schedul

      5/1/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

       Raised $52.8 million in gross proceeds in Q4 2024 to support the upcoming ZUNVEYL commercial launch and Nasdaq uplisting (symbol: ACOG). Completed commercial manufacturing to support the ZUNVEYL launch. Successfully completed the first phase of a pre-clinical bomb-blast study funded by a Department of Defense grant, demonstrating benzgalantamine's efficacy and safety in treating head trauma from simulated bomb blasts. Cash and cash equivalents of $48.6 million as of December 31, 2024, compared to $3.7 million as of September 30, 2024 and $1.4 million as of December 31, 2023. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cogn

      3/31/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

      Conference Call Scheduled for March 31, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the lin

      3/19/25 4:30:00 PM ET
      $ACOG